corner
Healthy Skepticism
Join us to help reduce harm from misleading health information.
Increase font size   Decrease font size   Print-friendly view   Print
Register Log in

Healthy Skepticism Library

Items published during the years 1990 to 1999

There are 2362 items in the Healthy Skepticism Library that were published during the years 1990 to 1999.

Page 3 of 24 pages  < 1 2 3 4 5 >  Last ›

HSL6837
Sales representatives: a damning report by Prescrire reps monitoring network
Prescrire International 1999; 8:(41):86-89

HSL6838
Angell M, Wood AJJ.
Authors’ conflicts of interest: a disclosure and editors’ reply
New England Journal of Medicine 1999; 341:1618-1619

HSL6840
Ashraf H.
MCA reconsiders drug advertising on the web
Lancet 1999; 353:2136

HSL6842
Bradbury J.
Storm over WHO-ISH hypertension guidelines
Lancet 1999; 353:563

HSL6845
Djulbegovic B, Bennett CL, Lyman GH.
Violation of the uncertainty principle in conduct of randomized controlled trials (RCTs) of erythropoietin (EPO)
Blood 1999; 94:(supplement 1):399a

HSL6847
Donovan J.
Advertising pharmaceuticals to Australian
Australian Prescriber 1999; 22:74-75
http://www.australianprescriber.com/magazines/vol22no4/editorial.htm

HSL6848
Dorman PJ, Counsell C, Sandercock P.
Reports of randomized trials in acute stroke, 1955 to 1995:What proportions were commercially sponsored?
Stroke 1999; 30:1995-8
http://stroke.ahajournals.org/cgi/content/full/30/10/1995

HSL6851
Ford AR
A different prescription: considerations for women’s health groups contemplating funding from the pharmaceutical industry
Toronto: National Network on Environment and Women’s Health 1999

HSL6856
Herxheimer A.
Leaflets with NSAIDs do not warn users clearly—a UK survey
Pharmaceutical Journal 1999; 262:559-561

HSL6857
Hoffman JR, Wilkes M.
Direct to consumer advertising of prescription drugs: An idea whose time should not come.
BMJ 1999; 318:1301-2
http://www.bmj.com/cgi/content/full/318/7194/1301

HSL6863
Lexchin J.
Direct-to-consumer advertising: impact on patient expectations regarding disease management
Disease Management & Health Outcomes 1999; 5:273-283

HSL6864
Lexchin J.
Following the rules in marketing
Canadian Medical Association Journal 1999; 161:685-686
http://www.cma.ca/cmaj/vol-161/issue-6/letters-6.htm#4

HSL6867
Lexchin J.
To the editor
Journal of Emergency Medicine 1999; 17:905

HSL6868
Liebeskind DS, Kidwell CS, Saver JL.
Empiric evidence of publication bias affecting acute stroke clinical trials
Stroke 1999; 30:268

HSL6870
Direct-to-consumer pharmaceuticals: media trends, market leaders, market size, market growth and more
Magazine Publishers of America 1999
www.magazine.org

HSL6871
Magazines: a healthy diagnosis. Return on investment for DTC pharmaceutical advertising. A study measuring the effectiveness of allergy advertising by PERZ/HCI
Magazine Publishers of America 1999
www.magazine.org

HSL6874
Marley J.
Complaints: a personal view
Australian Prescriber 1999; 22:80
http://www.australianprescriber.com/magazines/vol22no4/complaints.htm

HSL6878
Qizilbash N, Schneider L, Farlow M, Whitehead A, Higgins J.
Meta-analysis of tacrine for Alzheimer disease: the influence of industry sponsors
JAMA 1999; 281:2287-2288
http://jama.ama-assn.org/issues/v281n24/ffull/jlt0623-7.html

HSL6879
Roberts I.
Competing interests still exist
BMJ 1999; 318:465
http://www.bmj.com/cgi/content/full/318/7181/464/a#resp3

HSL6880
Rosen P.
Response to letter to the editor
Journal of Emergency Medicine 1999; 17:905

HSL6881
Roughead EE.
The Australian Pharmaceutical Manufacturers Association Code of Conduct: guiding the promotion of prescription medicines
Australian Prescriber 1999; 22:78-80
http://www.australianprescriber.com/magazines/vol22no4/conduct.htm

HSL6883
Sansgiry S, Sharp WT, Sansgiry SS.
Consumer understanding and interpretation of printed over-the-counter drug advertisements
Journal of Pharmaceutical Marketing & Management 1999; 13:(1):15-26

HSL6884
Shalansky S.
Conflicting opinions on conflict of interest
Canadian Journal of Hospital Pharmacy 1999; 52:67-68

HSL6885
Smith D
The ties that bind? Weighing the risks and benefits of pharmaceutical industry sponsorship
Amsterdam: Health Action Interaction 1999
www.haiweb.org

HSL6914
Haynes RB.
Drug dependence in a journal club: Editor's response
ACP Journal Club 1999; 131:(3):A13
http://www.acpjc.org/Content/131/3/ISSUE/ACPJC-1999-131-3-A13.htm

HSL7844
Jones M, Greenfield S, Bradley C.
Survey of the advertising of nine new drugs in the general practice literature
Journal of Clinical Pharmacy and Therapeutics 1999; 24:(6):451-460
www.blackwell-synergy.com/rd.asp?code=JCP&vol=24&page=451&goto=abstract

HSL7935
O'Connell CA, Skinner R.
Patient labeling program at Bristol-Myers Squibb
Drug Information Journal 1999; 33:(3):649-654

HSL7967
U.S. pharmaceutical industry spent more than $5.8 billion on product promotion in 1998: direct-to-consumer advertising expenditures exceed $1.3 billion
Massachusetts Pharmacy Journal 1999; 11:(1):12

HSL7975
Danjoh K.
Thinking globally: product development, registration, and marketing in the new millennium
Drug Information Journal 1999; 33:(1):327-332

HSL8137
McKechnie S.
Advertising by pharmaceutical companies in eBMJ.
BMJ 1999; 318:(7183):598
http://www.bmj.com/cgi/content/full/318/7183/598

HSL9053
Irwig J, Irwig L, Sweet M.
Smart Health Choices: How to make informed health decisions
Sydney: Allen & Unwin 1999
http://www.allenandunwin.com/Shopping/ProductDetails.aspx?ISBN=9781865081465

HSL10270
Harada K, Yamazaki S, Arakawa M, Fujimura A.
Survey of the attitudes of pharmacists and medical reprsentative toward drug interactions in daily practice
Japanese Journal of Clinical Pharmacology and Therapeutics 1999; 30:(6):783-791

HSL15128
Chaiken S, Trope Y.
Dual-process theories in social psychology.
New York: Guilford Press 1999
http://books.google.com.au/books?id=5X_auIBx99EC

HSL16245
Fried S
Bitter Pills: Inside the Hazardous World of Legal Drugs New York: Bantam Books 1999
http://www.stephenfried.com/bitter-pills/

HSL19055
Schwartz LM, Woloshin S.
Patient decision making: in search of good decisions.
Eff Clin Pract 1999; 2:(4):184
http://www.acponline.org/clinical_information/journals_publications/ecp/julaug99/woloshin.htm

HSL19056
Woloshin S, Schwartz LM.
How can we help people make sense of medical data?
Eff Clin Pract 1999; 2:(4):176-83
http://www.acponline.org/clinical_information/journals_publications/ecp/julaug99/schwartz.htm

HSL19761
Weston E
A Drug by Any Other Name: Brand Power in the Pharmaceutical Industry
New Doctor 1999; (71):2-7
http://www.drs.org.au/journal/71/71brand.htm

HSL19969
Concern over Roche's Advertising Campaign for Orlistat (Xenical) in the USA
Diabetes, Obesity and Metabolism 1999; 1:299-305
http://onlinelibrary.wiley.com/doi/10.1046/j.1463-1326.1999.00062.x/abstract;jsessionid=93551DB47591BB883A129783532E5C6A.d03t02?userIsAuthenticated=false&deniedAccessCustomisedMessage=

HSL20090
Banahan BF, Bentley JP, Sun LL, Lee KI
Physicians' attitudes toward and response to direct-to-consumer advertising
AAPS Pharm Sci 1999;
http://www.aapsj.org/abstracts/AM_1999/173.htm

HSL20091
Miller BL
Direct-to-consumer and over-the-counter advertising - What do consumers really think?
AAPS Pharm Sci 1999;

HSL20195
Chandra A, Holt GA
Pharmaceutical advertisements: How they deceive patients
Journal of Business Ethics 1999; 18:359-366
http://www.springerlink.com/content/m081503817315245/

HSL377
Jefferson BK.
Cal Ripken, Jr and Prinivil
;339(27):2024-5. N Engl J Med 1998 Dec 31; 339:(27):2024
http://content.nejm.org/cgi/content/extract/339/27/2024-a?andorexacttitleabs=and&search_tab=authors&tmonth=Dec&searchtitle=Authors&sortspec=Score+desc+PUBDATE_SORTDATE+desc&excludeflag=TWEEK_element&hits=20&tyear=1998&author1=Jefferson+BK&andorexactfulltext=and&fyear=1998&fmonth=Jan&sendit=GO&searchid=1124444608433_740&FIRSTINDEX=0&journalcode=nejm

HSL16734
Wolfe S, Lurie P
Troubling Climate at FDA
The Washington Post 1998 Dec 30

HSL5386
Wood AJ, Stein CM, Woosley R.
Making medicines safer--the need for an independent drug safety board.
N Engl J Med 1998 Dec 17; 339:(25):1851-4
http://content.nejm.org/cgi/content/extract/339/25/1851

HSL20028
Carter W
Christmas drug rep rush
New Zealand GP 1998 Dec 16

HSL20118
Wenley S
Changes to advertising code
New Zealand GP 1998 Dec 162

HSL8138
Blecher MB, Haugh R, Hudson T, Serb C.
The year that was--what it means for 1999.
Hosp Health Netw 1998 Dec 5-20; 72:(23-24):26-8,

HSL7971
Smith D.
Is your message lost among the rose petals?
Pharmaceutical Executive 1998 Dec; 18:18-19

HSL7972
Realto V.
Best of the best-1998 top 10
Pharmaceutical Executive 1998 Dec; 18:6-11

HSL8177
Mangino MH, Szajna JL, Ptachcinski R, Skledar SJ.
Role of a pharmacy technician in implementing a prescription assistance program for indigent and underinsured patients
ASHP Midyear Clinical Meeting 1998 Dec; 33:

HSL20417
Visser PS, Krosnick JA.
Development of attitude strength over the life cycle: surge and decline.
J Pers Soc Psychol 1998 Dec; 75:(6):1389-410
http://psycnet.apa.org/journals/psp/75/6/1389/

HSL410
Collier J.
Patient-information leaflets and prescriber competence.
Lancet 1998 Nov 28; 352:(9142):1724
http://www.thelancet.com/search/results?search_searchuri=%2Fsearch%2Fadvanced&search_resulturi=%2Fsearch%2Fresults&search_preview=no&search_reqfirst=1&search_reqcount=20&search_submode=advanced&update_search=no&search_mode=platform&search_cluster=phoenix&search_text1=Collier+J&search_within1=au&search_operator1=and&search_text2=leaflets&search_within2=ti&search_operator2=and&search_text3=&search_within3=all&restrictterm_lancet=lancet&restrictname_lancet=lancet&restricttype_lancet=journal&restrictdesc_lancet=The+Lancet&restrictname_laneur=laneur&restricttype_laneur=journal&restrictdesc_laneur=The+Lancet+Neurology&restrictname_laninf=laninf&restricttype_laninf=journal&restrictdesc_laninf=The+Lancet+Infectious+Diseases&restrictname_lanonc=lanonc&restricttype_lanonc=journal&restrictdesc_lanonc=The+Lancet+Oncology&search_dateradio=combo&search_datecombo=0%3AALL&search_monthstartcombo=1&search_yearstart=1996&search_monthendcombo=1&search_yearend=2005&search_wordsexactly=yes&search_sort=relevance&Submit=Search

HSL8160
Hui KK.
Adverse drug reactions in hospitalized patients.
JAMA 1998 Nov 25; 280:(20):1742-3

HSL2007
Langreth R.
Drug Marketing Drives Many Clinical Trials
The Wall Street Journal 1998 Nov 16

HSL6835
O’hara J.
Whistle-blower: a top researcher says a drug under trial poses a risk to patients
Maclean’s 1998 Nov 16

HSL8095
Fleming H.
Front-end success
Drug Topics 1998 Nov 16; 142:59-60, 62, 65, 67-68

HSL13868
Hankey GJ.
Heparin in acute ischaemic stroke: The T wave is negative and it's time to stop.
Med J Aust. 1998 Nov 16; 169:(10):534-6
http://www.ncbi.nlm.nih.gov/pubmed/9861911

HSL8169
Consumer ads build awareness but not understanding of advertised medications, surveys reveal
American Journal of Health System Pharmacy 1998 Nov 15; 55:2344, 2347

HSL20007
Gair K
Natural health reps knock on GPs' doors
Australian Doctor 1998 Nov 13

HSL3697
Scott L.
Patient visits up for DTC conditions.
Newtown, Pa. 1998 Nov 6
http://www.scottlevin.com

HSL4994
McGhan WF.
Employer and consumer perspectives.
Value Health 1998 Nov 01; 1:(4):237-42
http://www.blackwell-synergy.com/doi/abs/10.1046/j.1524-4733.1998.140237.x

HSL394
Lexchin J.
Drug not considered a first-line agent.
Can Fam Physician 1998 Nov; 44:2376

HSL398
Lal A.
Information contents of drug advertisements: an Indian experience.
Ann Pharmacother 1998 Nov; 32:(11):1234-8
http://www.theannals.com/cgi/reprint/32/11/1234

HSL6832
ACE inhibitors
Health Skepticism 1998 Nov; 1:(1):3-4

HSL6833
Law J.
Assessing the impact of direct-to-consumer advertising
Scrip Magazine 1998 Nov; (73):21-22

HSL6834
Lexchin J.
Re: the promotion of Longifene (buclizine)
1998 Nov;

HSL8110
Wechsler J.
Managed care and pharmaceutical costs
Pharmaceutical Executive 1998 Nov; 18:18, 20-22

HSL8111
Meinhardt RA.
Congress takes aim at retail pharmacy pricing
Drug Benefit Trends 1998 Nov; 10:21-22

HSL8136
Wechsler J.
Costs, coverage, and commercials
Pharmaceutical Technology 1998 Nov; 22:14, 16, 18, 20, 22-24

HSL8165
Pearson P, McWhinney P, Stanley P.
Resistance to antibiotics: Prescribing of antibiotics needs to be rational
British Medical Journal 1998 Nov; 317:1521
http://www.bmj.com/cgi/content/full/317/7171/1521/b

HSL384
Pieters T.
Marketing medicines through randomised controlled trials: the case of interferon.
BMJ 1998 Oct 31; 317:(7167):1231-3
http://bmj.bmjjournals.com/cgi/content/full/317/7167/1231

HSL8163
Sykes R.
Being a modern pharmaceutical company: involves making information available on clinical trial programmes.
BMJ 1998 Oct 31; 317:(7167):1172
http://www.bmj.com/cgi/content/full/317/7167/1172

HSL16733
Wolfe S, Sasich L, Barbehenn E
Safety of sildenafil citrate
Lancet 1998 Oct 24; 352:1393

HSL20273
Fairhurst K, Huby G
From trial data to practical knowledge: qualitative study of how general practitioners have accessed and used evidence about statin drugs in their management of hypercholesterolaemia
BMJ 1998 Oct 24; 317:(7166):1130–1134
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC28696/

HSL5313
Bates DW, Leape LL, Cullen DJ, Laird N, Petersen LA, Teich JM, Burdick E, Hickey M, Kleefield S, Shea B, Vander Vliet M, Seger DL.
Effect of computerized physician order entry and a team intervention on prevention of serious medication errors.
JAMA 1998 Oct 21; 280:(15):1311-6
http://jama.ama-assn.org/cgi/content/full/280/15/1311

HSL376
Shuchman M.
Legal issues surrounding privately funded research cause furore in Toronto.
CMAJ 1998 Oct 20; 159:(8):983-6
http://www.cmaj.ca/cgi/reprint/159/8/983

HSL385
Phillips RA, Hoey J.
Constraints of interest: lessons at the Hospital for Sick Children.
CMAJ 1998 Oct 20; 159:(8):955-7
http://www.cmaj.ca/cgi/reprint/159/8/955

HSL6831
Drug advertising
Shown on: Canadian Broadcasting Corporation program Undercurrents 1998 Oct 18

HSL370
A meeting too many.
Lancet 1998 Oct 10; 352:(9135):1161
http://linkinghub.elsevier.com/retrieve/pii/S0140673698000324

HSL6823
Bero LA.
Corporate gifts to academic researchers [2nd of 2 replies]
JAMA 1998 Oct 9; 280:(10):884

HSL6824
Campbell EG, Blumental D, Louis KS.
Corporate gifts to academic researchers [1st of 2 replies]
JAMA 1998 Oct 9; 280:(10):884

HSL20547
Abbasi K, Herxheimer A
The European Medicines Evaluation Agency: open to criticism
BMJ 1998 Oct 3; 317:(7163):898-900
http://www.bmj.com/content/317/7163/898

HSL20548
Kleinke JD, Gottlieb S
Is the FDA approving drugs too fast?
BMJ 1998 Oct 3; 317:(7163):899
http://www.bmj.com/content/317/7163/899

HSL415
Azimi NA, Welch HG.
The effectiveness of cost-effectiveness analysis in containing costs.
J Gen Intern Med 1998 Oct; 13:(10):664-9
http://www.blackwell-synergy.com/doi/abs/10.1046/j.1525-1497.1998.00201.x

HSL4782
Phatak A.
The pharmaceutical industry and the medical profession.
Issues Med Ethics 1998 Oct-Dec; 6:(4):131-2

HSL6787
Gabb G.
Striking a balance in drug information--the Australian Medicines Handbook.
Aust N Z J Med 1998 Oct; 28:(5):675

HSL6798
Shapiro JD, Phillips KA, Tannock IF.
More pharmaceutical company influence?
Aust N Z J Med 1998 Oct; 28:(5):675

HSL6822
Aslam N.
Pharmaceuticals lack seriousness to provide more information on request
The Network’s Drug Bulletin 1998 Oct-Dec; 7:(5-6):12-16, 19

HSL6828
The drug pushers
Health Which? 1998 Oct

HSL6829
Lexchin J.
Re: the promotion of Claribid (clarithromycin)
1998 Oct;

HSL6830
Rane W.
How ethical is the pharmaceutical industry in India
Rational Drug Bulletin 1998 Oct; 8:(4):4-5

HSL8116
Morais RJ.
Mastering the basics-10 steps to DTC
Pharmaceutical Executive 1998 Oct; 18:63-65

HSL8117
Wechsler J.
Consumer advocates & pharmacists attack DTC ads
Pharmaceutical Executive 1998 Oct; 18:8, 7

HSL8134
Waltermire RD.
Direct-to-consumer advertising of Rx drugs can be harmful to your health
Drug Benefit Trends 1998 Oct; 10:60-61

HSL8150
Ohliger PC.
Discount or illegal payment?
Drug Benefit Trends 1998 Oct; 10:27, 31

HSL8168
Murray MD, Deardorff FW.
Does managed care fuel pharmaceutical industry growth?
Pharmacoeconomics 1998 Oct; 14:(4):341-8

HSL6827
Public Citizen’s Health Research Group
Comments on: Food and Drug Administration: attitudinal and behavioral effects of direct-to-consumer advertising of prescription drugs
: Public Citizen’s Health Research Group 1998 Sep 28
www.citizen.org

HSL20016
Pharmaceutical industry praised
Australian Doctor 1998 Sep 258

HSL8133
Vecchione A.
All in one
Drug Topics 1998 Sep 21; 142:48

HSL18024
Berger A
The rise and fall of Viagra
BMJ 1998 Sep 19; 317:(7161):824
http://www.bmj.com/cgi/content/citation/317/7161/824

Page 3 of 24 pages  < 1 2 3 4 5 >  Last ›

 

  Healthy Skepticism on RSS   Healthy Skepticism on Facebook   Healthy Skepticism on Twitter

Please
Click to Register

(read more)

then
Click to Log in
for free access to more features of this website.

Forgot your username or password?

You are invited to
apply for membership
of Healthy Skepticism,
if you support our aims.

Pay a subscription

Support our work with a donation

Buy Healthy Skepticism T Shirts


If there is something you don't like, please tell us. If you like our work, please tell others.







Far too large a section of the treatment of disease is to-day controlled by the big manufacturing pharmacists, who have enslaved us in a plausible pseudo-science...
The blind faith which some men have in medicines illustrates too often the greatest of all human capacities - the capacity for self deception...
Some one will say, Is this all your science has to tell us? Is this the outcome of decades of good clinical work, of patient study of the disease, of anxious trial in such good faith of so many drugs? Give us back the childlike trust of the fathers in antimony and in the lancet rather than this cold nihilism. Not at all! Let us accept the truth, however unpleasant it may be, and with the death rate staring us in the face, let us not be deceived with vain fancies...
we need a stern, iconoclastic spirit which leads, not to nihilism, but to an active skepticism - not the passive skepticism, born of despair, but the active skepticism born of a knowledge that recognizes its limitations and knows full well that only in this attitude of mind can true progress be made.
- William Osler 1909